Immune-related dermatologic toxicities: to make a long story short.

Immune checkpoint inhibitors have demonstrated durable responses in some patient groups and gained regulatory approval for various cancer indications since 2011. Autoimmune and autoinflammatory adverse events, secondary to the use of such agents are known as "immune-related adverse events" (irAEs) and their incidence, severity and tolerability may vary among the classes of the checkpoint inhibitors. This short review provides an update and summarises the clinical manifestations and management of cutaneous irAEs induced by checkpoint inhibitors that are currently in use.